NBC19: Precision NLRP3 Inflammasome Inhibition for Advanced Inflammation Research

Executive Summary: NBC19 (SKU BA6129) is a small molecule inhibitor that targets the NLRP3 inflammasome with an IC₅₀ of 60 nM in differentiated THP1 cells (source: product_spec). It effectively suppresses IL-1β release induced by Nigericin (IC₅₀: 80 nM) and ATP (IC₅₀: 850 nM) (source: product_spec). NBC19’s molecular weight is 491.65 Da, and its chemical formula is C₂₄H₂₆BCl₃N₂O₂ (source: product_spec). The compound is stable when stored at -20°C and is primarily used in research to dissect inflammasome-driven cytokine pathways (source: product_spec). APExBIO provides NBC19 as a rigorously characterized reagent for reproducible inflammation studies.

Biological Rationale

The NLRP3 inflammasome is a cytosolic protein complex that detects cellular stress and danger signals, triggering caspase-1 activation and subsequent maturation of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and IL-18 (source: Yang et al., 2022). This pathway is central in the pathogenesis of sepsis, chronic inflammatory diseases, and metabolic syndromes. Excessive activation of NLRP3 contributes to tissue damage by amplifying cytokine release, as observed in both preclinical models and clinical studies. The development of selective small molecule inhibitors, like NBC19, enables precise interrogation and modulation of this complex, supporting the design of targeted anti-inflammatory strategies (source: Yang et al., 2022).

Mechanism of Action of NBC19

NBC19 acts as a direct inhibitor of the NLRP3 inflammasome. In cell-based assays, it prevents the assembly or activation of the NLRP3 complex, thereby blocking the downstream cleavage of pro-caspase-1 and the maturation and secretion of IL-1β. When THP1-derived macrophages are stimulated with Nigericin or ATP—both canonical NLRP3 activators—NBC19 suppresses IL-1β release in a concentration-dependent manner, with distinct potencies for each inducer (source: product_spec). This selectivity aligns with the compound’s molecular design, which is optimized for high-affinity binding to the NLRP3 complex. Notably, NBC19 does not indiscriminately inhibit unrelated inflammasome complexes, preserving experimental specificity (source: AImmunity article – Extends on workflow reproducibility guidance by adding updated potency values).

Evidence & Benchmarks

• NBC19 achieves an IC₅₀ of 60 nM for NLRP3 inhibition in differentiated THP1 cells (source: product_spec).
• Inhibition of Nigericin-induced IL-1β release occurs at 80 nM, while ATP-induced IL-1β release is suppressed at 850 nM (source: product_spec).
• Selective NLRP3 targeting enables dissection of inflammasome-dependent cytokine networks without off-target toxicity at recommended concentrations (source: AImmuno article – Clarifies integration into translational workflows, supplementing basic potency data).
• Storage at -20°C maintains NBC19’s stability; solutions are not recommended for long-term storage (source: product_spec).
• Recent cellular models show that lactate-driven HMGB1 release amplifies NLRP3-mediated inflammation, underlining the importance of precise inflammasome modulation (source: Yang et al., 2022).

Applications, Limits & Misconceptions

NBC19 is designed for in vitro and ex vivo study of NLRP3-mediated inflammation. Its nanomolar potency and selectivity make it suitable for cell-based assays, cytokine release studies, and mechanistic explorations of inflammasome signaling. Researchers use NBC19 to model disease-relevant immune responses and to test hypotheses on inflammasome-driven cytokine cascades. However, NBC19’s application is currently limited to research settings; its use in clinical or in vivo models requires further validation (workflow_recommendation). It is not intended for diagnostic or therapeutic applications in humans or animals (workflow_recommendation).

Common Pitfalls or Misconceptions

• NBC19 does not inhibit non-NLRP3 inflammasome complexes (e.g., AIM2 or NLRC4); experiments must confirm pathway specificity (source: AImmuno Mechanistic Insights – Extends on mechanism selectivity compared to previous reviews).
• Long-term storage of NBC19 solutions can lead to loss of activity; always prepare fresh dilutions (source: product_spec).
• Performance in species or cell types other than human THP1-derived macrophages may differ; confirm activity under each new experimental condition (workflow_recommendation).
• NBC19 is not a pan-cytokine inhibitor and does not broadly suppress all inflammatory mediators (workflow_recommendation).
• Extrapolation of in vitro potency to in vivo or clinical relevance is not established (workflow_recommendation).

Workflow Integration & Parameters

Protocol Parameters

• cell-based NLRP3 inhibition assay | 60 nM (IC₅₀, THP1 cells) | in vitro potency determination | Defines concentration for measurable inhibition of NLRP3 activity in differentiated THP1 cells | product_spec
• IL-1β release assay (Nigericin stimulation) | 80 nM (IC₅₀) | cytokine quantification post-NLRP3 activation | Quantifies efficacy in suppressing IL-1β release following canonical NLRP3 activation by Nigericin | product_spec
• IL-1β release assay (ATP stimulation) | 850 nM (IC₅₀) | ATP-induced inflammasome activation | Reflects potency for inhibition under ATP-driven NLRP3 activation | product_spec
• storage | -20°C | compound stability | Ensures product integrity for reproducible results | product_spec
• solution handling | prepare fresh; avoid long-term storage | workflow best practice | Prevents loss of activity and data variability | workflow_recommendation

Conclusion & Outlook

NBC19 stands out as a rigorously characterized, nanomolar-potent NLRP3 inflammasome inhibitor for research applications. Its robust, selective suppression of IL-1β release in THP1 models positions it as a critical tool for interrogating inflammatory signaling, especially in the context of sepsis and cytokine-driven disease models (source: Yang et al., 2022). Researchers can leverage NBC19 to clarify mechanistic links between metabolic stress (such as lactate-driven HMGB1 release) and NLRP3 activation, advancing our understanding of inflammation. For further scenario-driven workflow guidance, see the related article here—this article expands on practical integration and data integrity, supplementing the mechanistic focus above.

For product details and ordering, visit the NBC19 product page from APExBIO.